Jain Global’s Travere Therapeutics TVTX Stock Holding History

Jain Global’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.9M	Buy	+51,072	New	+$2.26M	0.01%	688
2025 Q4	–	Sell	-32,117	Closed	-$768K	–	1529
2025 Q3	$768K	Buy	+32,117	New	+$604K	﹤0.01%	681
2025 Q2	–	Sell	-101,695	Closed	-$1.82M	–	1621
2025 Q1	$1.82M	Buy	+101,695	New	+$2.06M	0.02%	369

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jain Global's TVTX Position: Q2 2026 in Review

Jain Global opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 51,072 shares worth $2.9M. The stake represents 0.01% of the portfolio and ranks #688 among its holdings. This is a return to the name: Jain Global previously reported a position in TVTX as recently as Q3 2025.

Jain Global first reported a position in TVTX in Q1 2025 and has held it in 3 quarters since. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Jain Global held 51,072 shares of Travere Therapeutics worth $2.9M as of Q2 2026.
Travere Therapeutics was a new Jain Global position in Q2 2026.
Travere Therapeutics made up 0.01% of Jain Global's portfolio in Q2 2026, its #688 holding.
Jain Global first reported a position in Travere Therapeutics in Q1 2025 and has held it in 3 quarters since.
320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Jain Global's 13F filing for Q2 2026, filed 14 Aug 2026.